Eckert & Ziegler BEBIG, Mick Radio-Nuclear Instruments, WOLF-Medizintechnik (WOmed)

Press Releases

We are keeping you informed! If you have questions regarding our press releases, feel free to contact us via the website´s contact form. Stay up-to-date with our companies latest news:
 
Print

First patients in Germany treated with I-125 IsoSeed® S17plus for LDR prostate brachytherapy

Seneffe, Belgium, February 22, 2016, Eckert & Ziegler BEBIG announces that the first patients in Germany have been treated with the new I-125 IsoSeed® S17plus which was launched earlier this year. The treatments were performed by the two Berlin based LDR prostate brachytherapy specialists, Dr. Thomas Oliver Henkel and Dr. Frank Kahmann.

"After using I-125 IsoSeed® S17 for the last 10 years, we have now started working with I-125 IsoSeed® S17plus and were satisfied with the results" stated both of  the urologists, Dr. Henkel and Dr. Kahmann. The new seed is available in an apparent activity between 0.197 and 0.926 mCi.

According to Dr. Kahmann, IsoSeed® S17plus with its full-length silver marker provides the same high degree of visibility under X-ray, fluoroscopy, CT-scan, MRI and ultrasound as seen with the IsoSeed® S17. "We have performed ten treatments so far with class 11 IsoCord® stranded seeds and are pleased with the results."

Eckert & Ziegler BEBIG has been selling IsoSeed® S17 worldwide since 2005 and had launched the new sealed source model in January 2016.

About LDR brachytherapy

In this form of treatment, small radioactive iodine-125 sources, so called seeds, are placed inside the prostate. By placing the seeds evenly throughout the organ, the prostate is covered with the designated dose required to destroy the cancerous cells. Since irradiation is mainly localized around the radioactive source, neighboring tissues are spared unnecessary damage.

LDR or permanent brachytherapy is the most conservative treatment method for early-stage prostate cancer. Its international popularity has increased continuously since the early 1990s and it is now generally accepted as a state-of-the art therapy. Prostate seed implantation is an effective and well-tolerated method for curing prostate cancer. The cure rates are comparable to the ones of external beam radiation therapy and prostatectomy for early-stage prostate cancer.

About Eckert & Ziegler BEBIG

Contributing to saving lives!

Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry. Its core business is the production and distribution of medical products for the treat­ment of cancer using brachytherapy. The company's headquarters are in Belgium, with production facilities in Germany and in the USA, as well as subsidiaries throughout Europe, the USA, India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing and distribution of its product line. The company's products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists.
Eckert & Ziegler BEBIG employs approximately 150 people. The company has been listed on the Euronext stock exchange since April 1997.

Contact:
Annica Witt
Marketing Communication Manager
marketing@bebig.com
www.bebig.com

Back